996 results about "Methionine" patented technology

The invention relates to the technical field of gene engineering and enzyme engineering, in particular to an esterase mutant for degrading ethyl carbamate and application of the esterase mutant, the esterase mutant has an amino acid sequence as shown in SEQ ID NO.1 which is subjected to site mutation, the site mutation is any one or more site combined mutation of V129S, V161L or I229M, and the amino acid sequence of the esterase mutant is shown in SEQ ID NO.1. The V129S site mutation is that valine at the 129 site is mutated into serine, the V161L site mutation is that valine at the 161 site is mutated into leucine, and the I229M site mutation is that isoleucine at the 229 site is mutated into methionine. Mutation is carried out through a site-directed mutagenesis method, so that the amino acid sequence of the esterase mutant V129S / I229M is changed, the autoplasmic structure and function of eggs are changed, the esterase mutant V129S / I229M with the ethyl carbamate hydrolysis rate increased to 6.55 times in an acid environment is finally obtained, and the esterase mutant V129S / I229M has high industrial application value.

The invention relates to the field of polypeptide compositions, in particular to a polypeptide metal chelate and application thereof in the field of cosmetics, and the polypeptide metal chelate is formed by chelating a polypeptide compound and a metal ion compound. The structure of the polypeptide compound is [gamma-Glu] n-AA, n is greater than or equal to 1, and AA is selected from glycine, alanine, valine, leucine, isoleucine, methionine (methionine), proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, asparaginic acid, glutamic acid, lysine, arginine or histidine; the polypeptide chelated zinc prepared by the invention has remarkable oil control and anti-inflammatory effects, and can be compounded with other raw materials to form cosmetics with oil control and acne removal effects.

The invention discloses a hybrid sturgeon feed and a preparation method thereof, and relates to the technical field of sturgeon feeds, and the key point of the technical scheme is that methionine and lysine are supplemented in a feed in which soybean protein concentrate replaces fish meal, so that the influence of methionine and lysine on the growth performance, liver and intestinal health and muscle quality of hybrid sturgeons is improved. The soybean protein concentrate is used for replacing the fish meal, so that the dosage and production cost of the fish meal are greatly reduced, and meanwhile, the methionine and the amino acid are added, so that the negative influence caused by replacing the fish meal with the soybean protein concentrate is avoided.

The invention discloses a method for regulating the transport activity of a strain to 1-aminocyclopropane-1-carboxylic acid, and relates to the technical field of bioengineering. The method for regulating and controlling the transport activity of the strain to 1-aminocyclopropane-1-carboxylic acid and / or methionine analogues and the tolerance of the strain to the 1-aminocyclopropane-1-carboxylic acid and / or methionine analogues, disclosed by the invention, comprises the step of transferring a LeuE gene into escherichia coli to obtain an escherichia coli recombinant strain with corresponding functions. The invention discloses the application of the LeuE protein and the LeuE gene in regulating and controlling the transport activity of escherichia coli to the 1-aminocyclopropane-1-carboxylic acid and / or methionine analogue and the tolerance of escherichia coli to the 1-aminocyclopropane-1-carboxylic acid and / or methionine analogue for the first time. The invention discloses that LeuE is an optimal candidate gene for constructing ACC synthetic bacteria for the first time, and the substrate specific transport of the LeuE meets the aim of enhancing the ACC tolerance of cells without influencing precursor supply.

There is provided a fluorinase variant thereof having at least 70% sequence identity to a sequence MSDLGX6TDDSVAQCKGLMLSICPX24VX26IX28DX30CHX33MTPX37DVVEGARYIVDLPR X52FPEGTVFATTTYPATGTX70X71RSVAX76RX78KX80AALGGARGQX90AGSGX95GX97E RAEGX103YIYIAPNNGLLTX116VIEEHGYX124EAYEVSX131TX133VIPX137X138PEPTFYSR EMVAIPSAHLAAGFPLX163X164VGRX168LX170DX172EIVRFEX179X180KX182X183X184VX186G X188X189LX191GX193X194X195X196X197DHPFGNX204WTNX208HRTDLEKAGIX219YX221TX223X 224KX226VX228DGVLX233FX235LPLX239PTFADAX246X247X248GX250PVX253YX255NSRGYLX2 62X263ARNAAX269LAYPYNLX277AGX280SVX283VTX286A (SEQ ID NO: 1), wherein X is a natural amino acid, and wherein the variant comprises one or more mutations at a site selected from the group consisting of an ion-egress site, a S-Adenosyl-L-Methionine (SAM) binding site, an ion-binding site (IBS), and a conserved site. Also disclosed are polynucleotides encoding the variants, vectors comprising the polynucleotides encoding the variants, and host cells comprising the vectors thereof. Also disclosed are Methods for producing the variants, methods of catalyzing the fluorination of a compound, uses of the fluorinase variants, and methods of treatment using the fluorinase variants thereof.

The invention relates to laccase as well as a mutant and application thereof, and belongs to the technical field of biology. The amino acid sequence of the laccase PnLac1 is as shown in SEQ ID NO. 2, and the nucleotide sequence of the laccase PnLac1 is as shown in SEQ ID NO. 1. The mutant is characterized in that aspartic acid at the 166th position of laccase PnLac1 is subjected to site-specific mutagenesis, histidine at the 348th position of laccase PnLac1 is subjected to site-specific mutagenesis, methionine at the 403th position of laccase PnLac1 is subjected to site-specific mutagenesis, or leucine at the 467th position of laccase PnLac1 is subjected to site-specific mutagenesis, amino acid sequences are shown as SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8 and SEQ ID NO.10, and nucleotide sequences are shown as SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7 and SEQ ID NO.9. The decoloring efficiency of the laccase PnLac1 on crystal violet reaches 5h, and the degradation rate reaches 75%. When the ABTS is used as a substrate, the enzyme activities of the laccase mutants H348F and L467M are respectively improved by 1.89 times and 1.65 times, and the ABTS has the potential of degrading stubborn substances; when guaiacol is used as a substrate, the enzyme activities of the laccase mutants D166A and M403F are respectively improved by 2.07 times and 3.72 times, and the guaiacol has a relatively high application prospect in the field of lignin.

The invention relates to the technical field of biological catalysis, and discloses an M88V mutant enzyme for preparing rebaudioside I. The M88V mutant enzyme is obtained by the following mutations generated by UGT76G1: M88V: methionine of the 88th amino acid sequence of UGT76G1 is mutated into valine. Aiming at the technical bottlenecks of low RI yield and poor selectivity in the existing RA biotransformation process, an efficient solution is provided for the UGT76G1 mutant developed by the invention. The mutant can specifically catalyze conversion from RA to RI, and the conversion rate of a target product is remarkably increased to 65% or above from general less than 7%. The excellent catalytic performance of the catalyst is verified in milliliter-level to upgraded reaction systems, the key problems of conversion efficiency and process amplification are solved, and a foundation is laid for large-scale green manufacturing of a high-added-value product RI.

The invention discloses a high-activity TET dioxygenase mutant as well as a construction method and application thereof. The TET dioxygenase mutant is obtained from an amino acid sequence of wild type TET dioxygenase as shown in SEQ ID NO.1 according to any one of the following mutation modes: a, the 150th proline is mutated into alanine; and b, proline at the 150th site is mutated into alanine, and isoleucine at the 235th site is mutated into methionine. The TET dioxygenase mutant provided by the invention can be stabilized in an escherichia coli system, the purification effect is good, the preparation difficulty is reduced, and the activity is remarkably improved compared with that of a wild type. The methylation gene transformation effect is far better than that of a traditional bisulfite transformation method, and the method has a good application prospect.

Soybean plants producing seeds and soybean seeds comprising increased protein content are provided. Also provided are soybean plants producing seeds and soybean seeds comprising increased amounts of essential amino acids such as methionine, tryptophan or lysine. Protein compositions having increased essential amino acids can be made from the soybean seeds. Additionally, methods for generating and using plants, seeds and protein compositions having increased protein content or increased amounts of essential amino acids are disclosed.

The invention belongs to the field of feeds, and discloses a biological feed containing a microbial microcapsule preparation and a preparation method of the biological feed. The biological feed is prepared from the following components in parts by weight: 90 to 93 parts of wall-broken rhodopseudomonas palustris powder, 2 to 3 parts of lysine hydrochloride, 0.1 to 0.5 part of methionine, 0.1 to 0.5 part of threonine, 0.3 to 1 part of arginine, 2 to 3 parts of calcium hydrophosphate, 1 to 2 parts of calcium carbonate, 0.5 to 1.2 parts of an antioxidant additive, 0.3 to 0.8 part of modified nano montmorillonite and 1 to 5 parts of a microbial microcapsule preparation. According to the biological feed, the wall-broken rhodopseudomonas palustris serves as basic nutrition and a main microorganism source of the feed and is matched with the compound probiotics of the microorganism micro-capsule preparation, the intestinal nutrition utilization rate is effectively increased, meanwhile, the antioxidant additive is added, and the problems that a single additive is narrow in function and prone to oxidation are solved; the modified nano montmorillonite is added to solve the problem of antagonism of toxin adsorption and mineral absorption.

A boron carrying agent, a preparation method therefor, and a pharmaceutical formulation. The boron carrying agent contains compound 1, N-4-carboxyphenylboronic acid amide-threonine-phenylalanine-phenylalanine-tyrosine-glycine-glycine-serine-arginine-glycine-lysine-arginine-aspartic acid-aspartic acid-phenylalanine-lysine-threonine-glutamic acid-glutamic acid-tyrosine-cysteine, having a molecular formula of C114H158BN30O35S1 and a molecular weight of 2552.4, and further contains compound 2, N-4-carboxyphenylboronic acid amide-arginine-lysine-lysine-lysine-arginine-arginine-glutamine-arginine-arginine-arginine, and / or compound 3, N-4-carboxyphenylboronic acid amide-methionine-alanine-serine-methionine-threonine-glycine-glycine-glutamine-glutamine-methionine-glycine. Compounds 1-3 can serve as a targeted medicament for boron neutron capture therapy used for treating a cerebral glioma and a head and neck tumor.

The invention belongs to the technical field of microbial fermentation, and discloses torulopsis variabilis and application thereof. Wild torulopsis variabilis is separated from soy sauce mash, a strain of torulopsis variabilis with high yield of aspartic acid, threonine, glutamic acid, valine, methionine, isoleucine, leucine and lysine is obtained through ARTP mutagenesis, the collection number of the torulopsis variabilis ZB444 is GDMCC No: 65240, the classification name of the Latin name of the torulopsis variabilis is Wickhamiella versitis, the collection number of the torulopsis variabilis ZB444 is CGMCC No: 65240, and the collection number of the torulopsis variabilis ZB444 is CGMCC No: 65240. The strain is preserved in Guangdong Microbial Culture Collection Center on October 12, 2024. The strain is applied to soy sauce fermentation, the content of various amino acids and the content of total amino acids in soy sauce can be increased, the nutritional value of the soy sauce can be increased, and meanwhile the flavor of the soy sauce is enhanced.

The invention relates to a betaine phosphate-containing feed additive for improving net energy level and a preparation method and application thereof, and belongs to the technical field of feed additives, the preparation method comprises the following steps: preparing composite betaine phosphate, preparing composite zinc methionine, and mixing; the preparation of the composite betaine phosphate comprises the following steps: preparing a betaine phosphate crude product, preparing a composite silicon dioxide carrier, and crystallizing; the preparation of the compound zinc methionine comprises the following steps: preparing an activated silicon dioxide carrier, adsorbing starch and adsorbing the zinc methionine; in the step of mixing, the compound betaine phosphate and the compound zinc methionine are mixed and then stirred at room temperature, and the betaine phosphate-containing feed additive capable of improving the net energy level is obtained. The feed additive prepared by the invention has a strong effect of improving the net energy level of broiler chickens, is not easy to have the problems of bonding and clustering, and is good in storage resistance.

The invention discloses a mutant with improved catalytic activity of S-adenosylmethionine synthetase and application of the mutant, and belongs to the technical field of biological enzyme engineering. According to the present invention, the site 189, the site 234, the site 266 and the site 371 of the S-adenosylmethionine synthetase MAT are subjected to site-specific combinatorial mutation to obtain a series of mutants with improved enzyme activity, the I189V / V266H improvement is the most obvious, and the specific enzyme activity is 3.5833 + / -0.1373 U.mg <-1 >, which is improved by 1353.08% compared to the parent WT; and for a whole-cell catalysis system, the yield of S-ademetionine synthesized by the mutant I189V / V266H / Q234N / N371R reaches 1751.01 mg / L, and the increase is most obvious. The enzyme mutant provided by the invention has a wide application prospect in the production of S-adenosylmethionine and the construction of genetic engineering microorganisms of S-adenosylmethionine.

The invention relates to the technical field of biological catalysis, and discloses an M88A mutant enzyme for preparing rebaudioside I. The enzyme is obtained by the following mutations generated by UGT76G1: M88A: methionine of the 88th amino acid sequence of UGT76G1 is mutated into alanine; the key conversion rate of RI is greatly increased from 7% to 85% (increased by more than 12 times), and the utilization rate and economical efficiency of raw materials are remarkably improved; the method can be perfectly reproduced under any test scale (10mL, 100mL and 5L), the conversion rate is always anchored to be more than 85%, and incomparable stability and amplification potential are shown.

The invention provides pantoea agglomerans and application thereof, and belongs to the technical field of microorganisms, the strain is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36122; the strain has very high selenium tolerance and transformation capacity, and can transform inorganic selenium (such as Se (IV)) with relatively high toxicity into organic selenium (such as selenomethionine and selenocystine) with low toxicity and zero-valent nano-selenium (Se0) in a culture medium containing sodium selenite. The pantoea agglomerans obtained by the invention has the characteristics of selenium-addictive microorganisms, and has potential application value in biotransformation of selenium, microbial synthesis of nano-selenium, and growth promotion and selenium enrichment of crops. The pantoea agglomerans can promote plant growth, a liquid fermentation process developed by the strain is utilized, the highest conversion rate of organic selenium can reach 92.5%, and the synthesis efficiency of nano-selenium reaches 88.3%. And development of organic selenium agricultural products is well facilitated.

The invention discloses a diluent for whole blood lateral immunochromatography detection as well as a preparation method and a detection method thereof, and belongs to the technical field of immunochromatography detection. The diluent solves the technical problems of unsmooth chromatography, background interference, poor stability of detection results and the like caused by red blood cells during direct detection of whole blood samples. The diluent comprises a buffer system, an osmotic pressure regulator glycine, a nonionic surfactant polysorbate, an erythrocyte aggregation inducer polyvinylpyrrolidone, a dynamic viscosity regulator trehalose, a blocking protein, a stabilizer combination L-methionine and L-histidine, and a composite formula of water. Red blood cells are effectively induced to gather and intercept on the sample pad through the synergistic effect of all the components, and meanwhile the stability of the chromatography process and the activity of the detection reagent are maintained. The diluent is mainly used for lateral immunochromatography quantitative detection of markers such as pro-enkephalin, C-reactive protein, cardiac troponin I or N-terminal pro-brain natriuretic peptide in a whole blood sample.

The invention relates to the technical field of pet feed additives, and discloses a feed additive capable of relieving animal hair falling and a preparation method of the feed additive capable of relieving animal hair falling. Comprising the following substances: 5 parts of an angelica sinensis extract, 10 parts of a cacumen biotae extract, 1.51 parts of vitamin B family, 0.1 part of vitamin H, 1 part of zinc, 0.1 part of selenium, 5 parts of methionine and 5 parts of cysteine. According to the feed additive capable of relieving animal hair falling, the hair quality can be improved, and hair falling can be reduced; the strength and the elasticity of hair are improved; healthy hair growth is promoted; the composition has the advantages that the health of the skin and hair follicles is enhanced, a better growth environment is provided for the hair, the healthy hair state of animals can be maintained, and the hair loss phenomenon caused by nutrition deficiency or environmental problems is reduced.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The invention provides a pichia pastoris strain for efficiently converting methanol to produce high-methionine-content single-cell protein and application of the pichia pastoris strain, and belongs to the technical field of biology. According to the invention, a strain of pichia pastoris (named as Pichiapastoris CN-SCP 00 with a preservation number of CCTCC (China Center For Type Culture Collection) NO: M2025657) is obtained through separation, and is subjected to multiple rounds of ARTP iterative mutation breeding, so that a strain Pichiapastoris CN-SCPYE421 (with a preservation number of CCTCC NO: M2025658) for efficiently converting methanol to produce single-cell protein containing high methionine is obtained. Compared with a commercial strain, the Pichiapastoris CN-SCPYE421 has higher methanol tolerance and utilization capacity, the fermentation time is remarkably shortened, and in addition, the Pichiapastoris CN-SCPYE421 can well grow at the temperature of 35 DEG C. The Pichiapastoris CN-SCPYE421 is subjected to fermentation culture in a 5L fermentation tank, the dry weight of thalli reaches 120-150g / L, the protein content reaches 65-75% of the dry weight of the thalli, the Pichiapastoris CN-SCPYE421 is rich in various essential amino acids, and the methionine content reaches 2.3%. The invention provides an excellent strain for industrial development of single-cell protein, and has great social significance and economic value for the feed protein industry.

The invention belongs to the technical field of soil organic matter improvers, and discloses a soil organic matter improver based on a compound microbial agent and a preparation method thereof, and the soil organic matter improver comprises the following components: a compound enzyme, a modified chitosan microsphere complex, a modified polyelectrolyte, an inhibitor L-methionine sulfoximine, a substrate, an auxiliary factor and the compound microbial agent. A compound enzyme system is used as a core, soil ammonium ions are circularly and efficiently assimilated through glutamine synthetase / glutamate synthetase, and the soil ammonium ions are converted into organic nitrogen; and energy guarantee is provided by virtue of polyphosphate kinase. The modified chitosan microsphere complex is used for protecting and slowly releasing enzyme and a substrate, and controlled release of the inhibitor L-methionine sulfoximine is realized through the modified polyelectrolyte, so that carbon-nitrogen balance of soil is regulated and controlled. The system has a synergistic effect with a compound microbial agent, the problem of soil organic matter reduction caused by excessive nitrogen application is effectively solved, meanwhile, the crop root biomass is remarkably increased, and the soil organic matter content is increased.

The invention discloses a method for efficiently producing ergothioneine by metabolic engineering modified escherichia coli and application, and belongs to the technical field of biology. By adopting the recombinant escherichia coli EGT-1-B * provided by the invention, glucose can be converted into ergothioneine; therefore, the raw materials are cheap and easy to obtain, additives and heavy metals which are harmful to human health are avoided, a good foundation is laid for later product purification, and the requirements of commercial application can be met. Furthermore, genes related to metabolism of histidine, methionine, cysteine and S-adenosylmethionine are further overexpressed in the recombinant escherichia coli EGT-1-B *, so that the content of precursor amino acid synthesized by the ergothioneine is increased, and meanwhile, after the gene yqaB is knocked out, the yield of the ergothioneine is further increased; the utilization rate of glucose to ergothioneine can be further improved, and the yield of ergothioneine can reach 140.29 mg / L.

The invention discloses a gelator and a preparation method and application thereof, the structural formula of the gelator is # imgabs0 #, R1 is a side chain group connected to an amino acid central carbon atom except an amino group, a carboxyl group and a hydrogen atom; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; r2 is alkyl with the carbon atom number of 16 to 19; and R3 is 9-fluorenyl methoxy carbonyl group or t-butyloxycarbonyl group. The gelator has a hydrophobic long alkyl tail chain, can spontaneously gather and assemble into a three-dimensional network structure through hydrogen bonds, pi-pi interaction and hydrophobic force, and fixes an oil phase in an oil solvent or an oil-water mixture in an effective manner to form high-strength gel.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The invention discloses a high-stability carbonyl reductase mutant and application of the high-stability carbonyl reductase mutant in chiral alcohol synthesis. An amino acid sequence as shown in SEQ ID NO.2 is mutated as follows: 20th leucine is replaced by any one of lysine, threonine, aspartic acid or isoleucine, and / or 55th leucine is replaced by any one of methionine, serine, lysine or isoleucine, and / or 55th leucine is replaced by any one of methionine, serine, lysine or isoleucine. Compared with a wild type enzyme, the stability of the obtained mutant is remarkably improved, particularly, single-point mutants Mut-L20I and Mut-L55I and a combined mutant Mut-L20I-L55I show excellent relative enzyme activity, thermal stability and substrate tolerance. The mutant has high catalytic activity and stability to various chiral alcohols, has the advantages of high catalytic efficiency, high thermal stability, strong substrate tolerance, easiness in fermentation production and the like, and is suitable for industrial application of enzymatic synthesis of chiral alcohols.

The invention relates to the field of plant molecular biology and forest genetic engineering, and particularly provides a PagRAP2.3 protein point mutant and application thereof in drought resistance of poplar. The mutant PagRAP2.3 MA is obtained by mutating methionine at the first site and cysteine at the second site of a wild type PagRAP2.3 protein into methionine and alanine. The invention further discloses a preparation method of the mutant PagRAP2.3. An expression vector containing the PagRAP2.3 MA gene is constructed, poplar 84K is transformed through an agrobacterium-mediated method, and a transgenic line with stable expression is obtained. Functional verification results show that overexpression of PagRAP2.3 MA can significantly increase the plant height of the poplar and promote plant growth, but the sensitivity to moisture is enhanced under drought stress. The mutant can be used for regulating and controlling the growth and development of forest trees and evaluating the drought resistance, and has a forestry breeding application prospect.

The invention provides a penicillin G acylase AxPGA mutant, an expression plasmid, a genetically engineered bacterium and application, and belongs to the technical field of biocatalysts. The mutant is obtained by mutation of any one or more of the following sites of an amino acid sequence as shown in SEQ ID NO: 1: (1) methionine at the 103rd site is substituted by cysteine, (2) tyrosine at the 424th site is substituted by phenylalanine, (3) tyrosine at the 442nd site is substituted by phenylalanine, and (4) tyrosine at the 451st site is substituted by alanine. The obtained penicillin G acylase AxPGA mutant is relatively high in enzyme activity and can be applied to high-conversion-rate and high-yield synthesis of beta-lactam antibiotics such as benicillin and amoxicillin.

The present application relates to a pyridoxal kinase mutant, a recombinant expression vector and a microbial cell and their applications, and belongs to the technical field of biological catalysis. In order to solve the problem of low product concentration in existing enzyme catalysis, a pyridoxal kinase mutant is provided, the amino acid sequence is selected from the amino acid sequence shown in SEQ ID NO. 1, the lysine at position 229 is mutated to alanine, phenylalanine, methionine, arginine, threonine, histidine, serine, tyrosine, valine, leucine, isoleucine, proline, asparagine, aspartic acid or glutamic acid; the pyridoxal kinase mutant is used for catalyzing pyridoxal to synthesize pyridoxal phosphate, and a recombinant expression vector and a microbial cell can be further formed. The present application has good enzyme activity, high product conversion rate, high concentration of pyridoxal phosphate obtained, and the concentration of the product catalyzed by the wild-type pyridoxal kinase to phosphorylate pyridoxal is obviously improved.

The invention discloses application of lobetyolin in preparation of a medicine for treating atherosclerosis, and belongs to the field of biological medicine. The atherosclerosis comprises atherosclerosis induced by a high methionine diet. Through verification, IL-33 in aortic tissues of ApoE <- / -> mice with high methionine diet is remarkably increased, and the expression level of IL-33 in the aortic tissues of the mice is remarkably reduced compared with that of a model group after the mice are treated by lobetyolin. It is proved that lobetyolin has a positive regulation effect on treatment of atherosclerosis. Through molecular docking analysis, the binding energy between the lobetyolin and the IL-33 is-7.3 kcal / mol, which indicates that the IL-33 and the lobetyolin have good binding stability. The invention provides a new idea for clinical treatment of atherosclerosis.

A liquid composition comprising a GLP-1 agonist or / and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and / or with long-acting insulin / insulin derivates where appropriate.